Owlstone Medical, Cambridge, UK, introduced the Respiratory Diseases Research Use Only (RUO) Panel. The breath biomarker panel, which is now commercially available, is intended to support research to distinguish between different types of chronic inflammatory airway diseases including asthma, chronic obstructive pulmonary disease (COPD), and idiopathic pulmonary fibrosis (IPF), and to facilitate better therapeutic decision making and monitoring.
Owlstone Medical’s Respiratory Diseases RUO Panel consists of a set of biologically relevant volatile organic compounds (VOCs) that have been linked to inflammatory respiratory diseases and can be easily collected on breath to enable direct characterization of disease biology in the lungs by non-invasively sampling the airways.
Available as an early output from the company’s test development process and supported by scientific publications and Breath Biopsy client study data, the panel will initially be offered for research use only as part of an expanded Breath Biopsy products and services offering to supplement the Breath Biopsy Omni Assay. It will be used by pharmaceutical and academic/clinical research clients to support therapeutic development through characterization of disease endotypes and monitoring response to therapy, and to better understand the onset, development, and exacerbation of disease.
Building from this panel, an in vitro diagnostic (IVD) is intended to be developed to support treatment decisionmaking through patient stratification and monitoring of therapeutic response.
“The Respiratory Diseases RUO Panel is the first to be commercially launched by Owlstone Medical and opens an important new phase in the application of breath to address areas of high clinical need,” says Billy Boyle, co-founder and CEO at Owlstone Medical. “Building on our recent announcement on the use of limonene as an EVOC probe in NASH/NAFLD, this panel further validates our strategy of identifying promising biomarkers from multiple sources including endogenous discovery, EVOC probes, and in-licensing. We look forward to making further announcements as our robust test pipeline continues to develop.”
For more information, visit Owlstone Medical.
